Integra LifeSciences (IART) Tops Q4 EPS by 1c; Offers 2022 Guidance

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.84, $0.01 better than the analyst estimate of $0.83. Revenue for the quarter came in at $405.5 million versus the consensus estimate of $403.4 million.

GUIDANCE:

Integra LifeSciences sees FY2022 EPS of $3.27-$3.35, versus the consensus of $3.42. Integra LifeSciences sees FY2022 revenue of $1.58-1.6 billion, versus the consensus of $1.63 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance